$ALDX
Aldeyra Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024089238 Filed on August 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.696M $3.038M
YoY Change 42.71% -10.11%
% of Gross Profit
Research & Development $12.44M $14.97M
YoY Change 78.71% 114.99%
% of Gross Profit
Depreciation & Amortization $62.99K $61.63K
YoY Change -10.01% -4.21%
% of Gross Profit
Operating Expenses $12.44M $14.97M
YoY Change 78.71% 44.74%
Operating Profit -$16.14M -$18.01M
YoY Change 68.97% 74.11%
Interest Expense $1.025M $477.6K
YoY Change 90.18% -64.77%
% of Operating Profit
Other Income/Expense, Net $1.025M $1.160M
YoY Change -24.86% -14.42%
Pretax Income -$15.11M -$16.85M
YoY Change 84.53% 87.47%
Income Tax
% Of Pretax Income
Net Earnings -$15.11M -$16.85M
YoY Change 84.6% 87.47%
Net Earnings / Revenue
Basic Earnings Per Share -$0.25 -$0.28
Diluted Earnings Per Share -$0.25 -$0.28
COMMON SHARES
Basic Shares Outstanding 59.42M 59.41M
Diluted Shares Outstanding 59.53M 59.41M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $112.7M $120.3M
YoY Change -21.34% -20.67%
Cash & Equivalents $68.12M $71.03M
Short-Term Investments $44.62M $49.30M
Other Short-Term Assets $3.977M $5.318M
YoY Change 39.81%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $116.7M $125.6M
YoY Change -20.71% -19.19%
LONG-TERM ASSETS
Property, Plant & Equipment $1.360K $2.720K
YoY Change -82.51% -98.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $267.3K
YoY Change
Total Long-Term Assets $598.6K $394.3K
YoY Change 728.69% 187.34%
TOTAL ASSETS
Total Short-Term Assets $116.7M $125.6M
Total Long-Term Assets $598.6K $394.3K
Total Assets $117.3M $126.0M
YoY Change -20.34% -19.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $186.9K $254.4K
YoY Change -24.38% -6.05%
Accrued Expenses $10.42M $5.843M
YoY Change 32.89% -38.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $280.0K $15.24M
YoY Change -97.92% 158.59%
Total Short-Term Liabilities $17.15M $27.59M
YoY Change -20.65% 76.83%
LONG-TERM LIABILITIES
Long-Term Debt $15.00M $0.00
YoY Change 464.51% -100.0%
Other Long-Term Liabilities $70.23K $138.9K
YoY Change
Total Long-Term Liabilities $15.00M $0.00
YoY Change 464.51% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.15M $27.59M
Total Long-Term Liabilities $15.00M $0.00
Total Liabilities $32.22M $27.73M
YoY Change 32.75% 7.77%
SHAREHOLDERS EQUITY
Retained Earnings -$434.3M -$419.2M
YoY Change 11.5% 9.93%
Common Stock $519.3M $517.5M
YoY Change 1.33% 1.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $85.10M $98.31M
YoY Change
Total Liabilities & Shareholders Equity $117.3M $126.0M
YoY Change -20.34% -19.0%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$15.11M -$16.85M
YoY Change 84.6% 87.47%
Depreciation, Depletion And Amortization $62.99K $61.63K
YoY Change -10.01% -4.21%
Cash From Operating Activities -$7.975M -$13.22M
YoY Change -0.69% -1.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $5.263M -$18.24M
YoY Change
Cash From Investing Activities $5.263M -$18.24M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -197.4K 0.000
YoY Change -38.32% -100.0%
NET CHANGE
Cash From Operating Activities -7.975M -13.22M
Cash From Investing Activities 5.263M -18.24M
Cash From Financing Activities -197.4K 0.000
Net Change In Cash -2.910M -31.46M
YoY Change -65.15% 135.63%
FREE CASH FLOW
Cash From Operating Activities -$7.975M -$13.22M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001341235
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36332
dei Entity Registrant Name
EntityRegistrantName
ALDEYRA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1968197
dei Entity Address Address Line1
EntityAddressAddressLine1
131 Hartwell Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 320
dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
761-4904
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
ALDX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59421551
CY2024Q2 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
31029723
CY2023Q4 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
142823016
CY2024Q2 aldx Cash Equivalent Reverse Repurchase Agreements
CashEquivalentReverseRepurchaseAgreements
40000000
CY2023Q4 aldx Cash Equivalent Reverse Repurchase Agreements
CashEquivalentReverseRepurchaseAgreements
0
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
49301960
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5317836
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4987317
CY2024Q2 us-gaap Assets Current
AssetsCurrent
125649519
CY2023Q4 us-gaap Assets Current
AssetsCurrent
147810333
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
391595
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
510814
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2720
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5764
CY2024Q2 us-gaap Assets
Assets
126043834
CY2023Q4 us-gaap Assets
Assets
148326911
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
254434
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1338057
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5842802
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5536464
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
15242327
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
15146546
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
255039
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
239183
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6000000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
27594602
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22260250
CY2024Q2 us-gaap Deferred Long Term Liability Charges
DeferredLongTermLiabilityCharges
0
CY2023Q4 us-gaap Deferred Long Term Liability Charges
DeferredLongTermLiabilityCharges
6000000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
138893
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
271631
CY2024Q2 us-gaap Liabilities
Liabilities
27733495
CY2023Q4 us-gaap Liabilities
Liabilities
28531881
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59414489
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59414489
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59195951
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59195951
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
59415
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
59196
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
517449424
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
513994982
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9658
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-419188842
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-394259148
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
98310339
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
119795030
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
126043834
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
148326911
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14969743
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6962907
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21153251
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18198767
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3038064
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3379750
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6248420
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8947167
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18007807
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10342657
us-gaap Operating Income Loss
OperatingIncomeLoss
-27401671
us-gaap Operating Income Loss
OperatingIncomeLoss
-27145934
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1637836
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1882800
us-gaap Investment Income Interest
InvestmentIncomeInterest
3448105
us-gaap Investment Income Interest
InvestmentIncomeInterest
3561685
CY2024Q2 us-gaap Interest Expense
InterestExpense
477601
CY2023Q2 us-gaap Interest Expense
InterestExpense
527141
us-gaap Interest Expense
InterestExpense
976128
us-gaap Interest Expense
InterestExpense
1018428
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1160235
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1355659
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2471977
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2543257
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-16847572
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8986998
us-gaap Net Income Loss
NetIncomeLoss
-24929694
us-gaap Net Income Loss
NetIncomeLoss
-24602677
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59414489
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59414489
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58791920
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58791920
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59414489
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59414489
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58791762
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58791762
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-16847572
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8986998
us-gaap Net Income Loss
NetIncomeLoss
-24929694
us-gaap Net Income Loss
NetIncomeLoss
-24602677
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6629
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-9658
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
103938
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-6629
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-9658
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
103938
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16854201
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8986998
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24939352
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24498739
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
119795030
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3436470
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
18191
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-9658
aldx Net Loss
NetLoss
-24929694
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
98310339
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
151008029
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3316058
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5292
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
52559
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
103938
aldx Net Loss
NetLoss
-24602677
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
129883199
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
113419441
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1745099
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-6629
CY2024Q2 aldx Net Loss
NetLoss
-16847572
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
98310339
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
137243213
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1621692
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5292
CY2023Q2 aldx Net Loss
NetLoss
-8986998
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
129883199
us-gaap Profit Loss
ProfitLoss
-24929694
us-gaap Profit Loss
ProfitLoss
-24602677
us-gaap Share Based Compensation
ShareBasedCompensation
3484366
us-gaap Share Based Compensation
ShareBasedCompensation
5763896
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
95781
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
187501
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
697119
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
14542
us-gaap Depreciation
Depreciation
122263
us-gaap Depreciation
Depreciation
131312
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
330519
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2918672
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1083623
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
137191
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
141560
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-7323007
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23196985
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22801654
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
60614499
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
12000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
30000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-48614499
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
30000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5292
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
18191
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
52559
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18191
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
57851
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-71793293
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7256197
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
142823016
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
144419364
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71029723
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
151675561
us-gaap Interest Paid Net
InterestPaidNet
884500
us-gaap Interest Paid Net
InterestPaidNet
823521
us-gaap Nature Of Operations
NatureOfOperations
<div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NATURE OF BUSINESS </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aldeyra Therapeutics, Inc., together with its wholly-owned subsidiaries (the “Company” or “Aldeyra”), a Delaware corporation, is a clinical-stage biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s principal activities to date include research and development activities along with related general business planning, including raising capital.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company’s management evaluates its estimates and assumptions on an ongoing basis. Management’s most significant estimates in the Company’s condensed consolidated financial statements include, but are not limited to, deferred and accrued research and development costs, stock-based compensation, and accounting for income taxes and related valuation allowance. Although these estimates and assumptions are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8765797
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8765797
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7775253
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7775253
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71029723
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
49301960
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
116897479
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
14312565
CY2024Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2024Q2 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
3859927
CY2023Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
4463783
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
1036223
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
340388
CY2024Q2 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
421686
CY2023Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
183146
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5317836
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4987317
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2571463
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3087937
CY2024Q2 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2411867
CY2023Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1687327
CY2024Q2 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
859472
CY2023Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
761200
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5842802
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5536464
CY2024Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2024Q2 aldx Supplemental End Of Term Charges
SupplementalEndOfTermCharges
251643
CY2023Q4 aldx Supplemental End Of Term Charges
SupplementalEndOfTermCharges
173646
CY2024Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
9316
CY2023Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
27100
CY2024Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
15242327
CY2023Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
15146546
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
15292500
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
15292500
aldx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
200000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1935529
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1573540
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3484366
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5763895
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5868816
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.4
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y5M8D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3996
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2376328
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
179897
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.9
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
31506
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.49
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8033741
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.57
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M8D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4829541
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M9D
CY2024Q2 us-gaap Share Price
SharePrice
3.31
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
400000
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
us-gaap Operating Lease Expense
OperatingLeaseExpense
140300
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
423132
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
29200
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
393932
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
255039
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
138893
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
393932
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
423132
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
137928
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
285204
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0
CY2024Q2 aldx Indemnification Obligations Claims Outstanding
IndemnificationObligationsClaimsOutstanding
0
CY2024Q2 aldx Cash Reserve For Indemnities And Guarantees
CashReserveForIndemnitiesAndGuarantees
0

Files In Submission

Name View Source Status
0000950170-24-089238-index-headers.html Edgar Link pending
0000950170-24-089238-index.html Edgar Link pending
0000950170-24-089238.txt Edgar Link pending
0000950170-24-089238-xbrl.zip Edgar Link pending
aldx-20240630.htm Edgar Link pending
aldx-20240630.xsd Edgar Link pending
aldx-ex10_1.htm Edgar Link pending
aldx-ex10_2.htm Edgar Link pending
aldx-ex31_1.htm Edgar Link pending
aldx-ex31_2.htm Edgar Link pending
aldx-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img130887665_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
aldx-20240630_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending